Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bayer HealthCare
Cyclin E and cyclin A expression in cervical carcinomas require further study
June 23rd, 2006
The expression pattern of cyclin E and cyclin A in cervical carcinomas requires further study. "Cyclin E levels are high during late G1 and early S-phase in normal cells. The cyclin E expression over the cell cycle in tumours is not fully known," investigators in Sweden reported. "The impact on patient outcome by high cyclin E levels during other parts of the cell cycle than late G1- and early S-phase is unknown," explained F. Erlandsson and colleagues, Bayer Healthcare. "We set out to study the expression of cyclin E over the cell cycle in cervical carcinomas. Using immunofluorescence staining of cyclin A, digital microscopy, and digital image...
Source: Biotech Law Weekly (2006-06-23)
|
